-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273

Benzinga·11/03/2026 14:55:05
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.